{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:50:20Z","timestamp":1790009420368,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ejca.2025.115560","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T15:11:44Z","timestamp":1749654704000},"page":"115560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS"],"prefix":"10.1016","volume":"225","author":[{"given":"Elisa","family":"Gobbini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Langlais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Missy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Chanoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Jean","family":"Souquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Barlesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisse","family":"Audigier-Valette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-C\u00e9cile","family":"M\u00e9tivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Monnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3941-3860","authenticated-orcid":false,"given":"Jos\u00e9","family":"Hureaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Jeannin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Cadranel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Lagrange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qu\u00e2n","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7510-2787","authenticated-orcid":false,"given":"Franck","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7965-2989","authenticated-orcid":false,"given":"Olivier","family":"Molinier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Westeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9909-2299","authenticated-orcid":false,"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Moro-Sibilot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115560_bib1","unstructured":"SEER Incidence Data, November 2023 Submission (1975-2021)."},{"key":"10.1016\/j.ejca.2025.115560_bib2","article-title":"Prevalence of polypharmacy and potentially inappropriate medications use in elderly Chinese patients: a systematic review and meta-analysis","volume":"13","author":"Tian","year":"2022","journal-title":"Front Pharm"},{"issue":"1","key":"10.1016\/j.ejca.2025.115560_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1158\/1055-9965.EPI-17-0523","article-title":"Potential Medication-Related problems in older breast, colon, and lung cancer patients in the United States","volume":"27","author":"Lund","year":"2018","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"4","key":"10.1016\/j.ejca.2025.115560_bib4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"ESMO guidelines committee. Electronic address: clinicalguidelines@esmo.org. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115560_bib5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","article-title":"Intestinal akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer","volume":"28","author":"Derosa","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ejca.2025.115560_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-10734-y","article-title":"Gut microbiota composition is associated with polypharmacy in elderly hospitalized patients","volume":"7","author":"Ticinesi","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2025.115560_bib7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2020.09.033","article-title":"Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index","volume":"142","author":"Buti","year":"2021","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2025.115560_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100353","article-title":"IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer","volume":"7","author":"Molinier","year":"2022","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.ejca.2025.115560_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001361","article-title":"Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice","volume":"8","author":"Cortellini","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2025.115560_bib10","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The National healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ejca.2025.115560_bib11","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejca.2021.03.041","article-title":"Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy","volume":"150","author":"Buti","year":"2021","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2025.115560_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/mbo3.1260","article-title":"Impact of antibiotics on the human microbiome and consequences for host health","volume":"11","author":"Patangia","year":"2022","journal-title":"Microbiologyopen"},{"issue":"17","key":"10.1016\/j.ejca.2025.115560_bib13","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1200\/JCO.22.00074","article-title":"Impact of antibiotic exposure before immune checkpoint inhibitor treatment on overall survival in older adults with cancer: a population-based study","volume":"41","author":"Eng","year":"2023","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.ejca.2025.115560_bib14","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell Death-1 and programmed Death-Ligand 1 blockade in patients with Non-Small-Cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2025.115560_bib15","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1093\/annonc\/mdx181","article-title":"Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy May compromise outcomes","volume":"28","author":"Connell","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115560_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103176","article-title":"Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives","volume":"157","author":"Marinelli","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ejca.2025.115560_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/1073274820985790","article-title":"Effect of systemic corticosteroid therapy on the efficacy and safety of nivolumab in the treatment of Non-Small-Cell lung cancer","author":"Umehara","year":"2021","journal-title":"Cancer Control"},{"issue":"1","key":"10.1016\/j.ejca.2025.115560_bib18","first-page":"5","article-title":"Opioid system modulates the immune function: a review","volume":"1","author":"Liang","year":"2016","journal-title":"Transl Perioper Pain Med"},{"key":"10.1016\/j.ejca.2025.115560_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/156720206778018767","article-title":"Morphine stimulates vascular endothelial growth factor-like signaling in mouse retinal endothelial cells","volume":"3","author":"Chen","year":"2006","journal-title":"Curr Neurovasc Res"},{"issue":"3","key":"10.1016\/j.ejca.2025.115560_bib20","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1213\/ANE.0b013e31820568af","article-title":"The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation","volume":"112","author":"Mathew","year":"2011","journal-title":"Anesth Analg"},{"issue":"1","key":"10.1016\/j.ejca.2025.115560_bib21","first-page":"116","article-title":"Immune checkpoint inhibitors and opioids in patients with solid tumours: is their association safe? A systematic literature review","volume":"11","author":"Cani","year":"2022","journal-title":"Healthc (Basel)"},{"key":"10.1016\/j.ejca.2025.115560_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.586760","article-title":"Pleiotropic effects of metformin on the antitumor efficiency of immune checkpoint inhibitors","volume":"11","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115560_bib23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/2326-6066.CIR-16-0103","article-title":"Efficacy of PD-1 blockade is potentiated by Metformin-Induced reduction of tumor hypoxia","volume":"5","author":"Scharping","year":"2017","journal-title":"Cancer Immunol Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925003429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925003429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:36:24Z","timestamp":1762342584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925003429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":23,"alternative-id":["S0959804925003429"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115560","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115560","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115560"}}